Brian I. Rini, MD, on Renal Cell Carcinoma: Data on Atezolizumab, Bevacizumab, and Sunitinib

April 13, 2021 By The ASCO Post Staff

Brian I. Rini, MD, of Vanderbilt University, discusses the IMmotion151 trial results on overall survival and the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (Abstract CT188).

Related Content